Evvy

• 28/09/2023
• Series A
• $14,000,000

Evvy is unlocking precision women’s healthcare through novel, overlooked female biomarkers — starting with the vaginal microbiome.

Backed by leading healthcare investors such as General Catalyst, Left Lane Capital, and LabCorp, the Evvy team includes leading OB/GYNs and vaginal microbiome researchers with decades of experience at organizations like UCSF, Stanford, Harvard, Cleveland Clinic, and more. Evvy is one of the fastest growing women’s health companies in the US — enabling us to deliver innovative, high quality care while scaling novel R&D to unlock a new, data-driven future in women’s health.

Evvy’s Vaginal Health Test is the first at-home vaginal microbiome test to use metagenomic sequencing to tell you what’s up down there, why it matters, and what you can do about it. Evvy’s larger platform is the first vaginal healthcare service to bring together state-of-the-art testing, precision clinical care, and 1:1 coaching to give women and people with vaginas the care they deserve. Through this platform, Evvy is building real-world datasets that can transform our understanding of complex female health conditions.

Imagine a world where female health is finally understood: where risks are detected early and precisely; conditions are defined with specificity and nuance; and diseases are treated with personalization and care. That’s the world that Evvy is pioneering.

---

---